Home
    Webcasting
    Registration
    Accommodation
    Contact
     Home
     Scientific Committee
     Welcome Note
     Topics
     Faculty
     Satellite Symposia
         Webcasting
     Timetable & Program
         Friday, February 6, 2009
         Saturday, February 7, 2009
         Sunday, February 8, 2009
     Poster Presentation Schedule
         Group A
         Group B
         Poster Presentation Guidelines
         E-Posters
     Congress Prize
         Awardees
     CME
     Registration
     Invitation Letter
     Accommodation
     Accompanying Persons Program
     Sponsorship & Exhibition
     Sponsors
     General Information
         Before you travel ...
     Official Airline Network
     Italian Agent
     Contact Us
The 2nd World Congress on
Controversies in Urology (CURy)
Lisbon, Portugal, February 5- 8, 2009
 
  Group B Print
Saturday, February 7, 2009
 
Board
Topic: Nephrolithiasis
 
75 UVA URSI FOR PREVENTION OF URINARY TRACT INFECTION IN ESWL TREATMENT
D. Durovic
, P. Dragoljub, D. Nale, D. Djordjevic
Department of Urology, Clinical Center of Montenegro, Podgorica Montenegro
76 IS TUBELESS PERCUTANEOUS NEPHROLITHOTOMY (PCNL) HERE TO STAY? A 2 YEAR SINGLE CENTRE EXPERIENCE
I. El-Mokadem
, T. Page, P. Menezes, P. English, R. Marsh, P. Johnson               
Urology Department & Radiology Department, Sunderland Royal Hospital, Sunderland, UK
77 NON-LITHIASIC ACUTE RENAL PAIN: COMPUTERIZED TOMOGRAPHY EVALUATION
P. Eufrasio
, M. Seco, B. Parada, A. Mota                       
Department Urology Renal Transplant, Hospitals of the University of Coimbra, Coimbra, Portugal
78 URETEROSCOPIC TREATMENT OF LARGE RENAL CALCULI (2 TO 4CM)
N. Leone
, S. Hubosky, A. Mariani, D. Bagley
Thomas Jefferson University Hospital, Ardmore, USA
79 COMPLICATIONS AFTER 5.000 RETROGRADE URETEROSCOPIES: A SINGLE-CENTRE EXPERIENCE
P. Geavlete
, D. Georgescu, R. Multescu, B. Geavlete                        
Department of Urology, "Saint John" Emergency Clinical Hospital, Bucharest, Romania
80 PCNL COMPLICATIONS AFTER 2,000 PROCEDURES
P. Geavlete
, V. Cauni, V. Mirciulescu, D. Georgescu, R. Multescu, B. Geavlete               
Department of Urology, "Saint John" Emergency Clinical Hospital, Bucharest, Romania
81 DOUBLE J INDWELLING – EXPERIENCE ON 10,000 PROCEDURES
P. Geavlete
, V. Mirciulescu, D. Georgescu, R. Multescu, B. Geavlete                   
Department of Urology, "Saint John" Emergency Clinical Hospital, Bucharest, Romania
82 THE EFFECTS OF TOLTERODINE EXTENDED RELEASE AND ALFUZOSIN FOR THE TREATMENT OF DOUBLE-J STENT-RELATED SYMPTOMS
S.C. Park
, H.J. Jeong, I.Y. Seo, J.S. Rim                        
Wonkwang University School of Medicine and Hospital, Iksan, Korea
83 EFFICIENCY AND SAFETY OF ESWL TREATMENT WITH AND WITHOUT DOUBLE-J STENT FOR KIDNEY STONES 10 TO 20 MM
D. Perovic
, P. Kavaric, D. Durovic, V. Brajovic
Department of Urology, Clinical Center of Montenegro, Podgorica, Montenegro
84 CHANGES OF PLASMA BETA-ENDORPHIN AND ADRENOCORTICOTROPHIC HORMONE LEVELS DURING EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY TREATMENT-RELEVANCE TO PAIN
M. Sunay
, A. Karabulut, L. Emir, D. Erol                       
1st Clinic of Urology, Ministry of Health Ankara Teaching and Research Hospital, Ankara, Turkey
85 MANAGEMENT OF PROXIMAL URETERAL CALCULI BIGGER THAN 10 MM: COMPARISION OF SWL, SEMIRIGID AND FLEXIBLE URETEROSCOPY
F. Yencilek
, K. Sarýca, C. Goktas, O. Canguven, S. Albayrak
Department of Urology Yeditepe University Medical Faculty, Istanbul, Turkey
                                  
Topic: Overactive Bladder
 

86

ANALYSIS OF FACTORS AFFECTING RE-TREATMENT AFTER COMPLETION OF INITIAL 12-WEEK TREATMENT WITH TOLTERODINE ALONE IN FEMALE PATIENTS WITH OVERACTIVE BLADDER SYMPTOMS
Y.B. Jeong
, H.K. Oh, M.W. Cheon, M.K. Kim, J.K. Park, H.J. Kim, Y.G. Kim
Chonbuk National University Medical School, Jeonju, Korea
87 LONG-TERM URODYNAMIC EFFECTS OF PERCUTANEOUS POSTERIOR TIBIAL NERVE STIMULATION ON NEUROGENIC DETRUSOR OVERACTIVITY IN PATIENTS WITH MULTIPLE SCLEROSIS
S. Kabay
, S.C. Kabay, M. Yucel, H. Ozden, Z. Yilmaz
Dumlupinar University, Kutahya, Turkey
88 CYTOKINES IN URINE INDICATES URETHRAL ORIGIN OF URGENCY IN THE “OVERACTIVE BLADDER SYNDROME”.
O. Lofgren
  
Gynhalsan, Trelleborg, Sweden
89 PROSTAGLANDIN E2 RELEASE BY THE BLADDER UROTHELIUM IS DICTATED BY A COMPLEX INTERACTION OF PHYSIOLOGICAL MEDIATORS; A ROLE IN SENSORY PROCESSING
C. Nile,
J. de Vente, G. van Koeveringe, J. Gillespie
Newcastle University, Newcastle, UK
90 INTRA-TRIGONAL INJECTION OF BOTULINUM TOXIN A IN PATIENTS WITH BLADDER PAIN SYNDROME: RESULTS AT 6-MONTHS OF FOLLOW-UP
R. Pinto
, A. Silva, T. Lopes, J. Silva, C. Silva, P. Dinis
Department of Urology - Hospital de S. Joao, Porto, Portugal
91 EFFECT OF SUB-THALAMIC STIMULATION IN LOWER URINARY TRACT SYMPTOMS
R. Pinto
, R. Oliveira, A. Silva, J. Silva, C. Silva, M. Guimaraes, M. Rosas, R. Vaz, F. Cruz
Department of Urology, Hospital de S. Joao, Porto, Portugal
92 EFFECT OF THE ORAL TRPV1 ANTAGONIST GRC 6211 ON BLADDER REFLEX ACTIVITY OF CHRONIC SPINALIZED RATS
A. Silva
, C. da Cruz, A. Charrua, R. Pinto, J. Silva, C. Silva, P. Dinis, F. Cruz
Department of Urology, Hospital de S.João, Alameda Prof. Hernani Monteiro, Porto, Portugal
93 DO PATIENTS’ PERCEPTIONS AND ATTITUDES TOWARDS TREATMENT OF OAB INFLUENCE COMPLIANCE WITH TREATMENT?
J.-J. Wyndaele
, G. Schaer, S. Al-Shukri, G. Notarianni, G. Compion
Department of Urology, University Hospital Antwerp, Antwerp, Belgium
                          
Topic: Prostate Cancer
 
94 MONITORING PROSTATE CANCER: THE SPANISH EXPERIENCE
A. Alcaraz
, F.J. Burgos, J.M. Cozar, F. Gomez-Veiga, J. Morote, E. Solsona, M. Unda, J. Carballido            
Hospital Clinic (IDIBAPS), Barcelona, Spain
95 DOES INFLAMMATION ON PROSTATE NEEDLE BIOPSY INCREASE THE LIKELIHOOD OF CANCER ON SUBSEQUENT BIOPSY? COMPARATIVE STUDY ABOUT 100 CASES
S. Ben Rhouma
, S. Sallami, M. Chelif, M. Tanguour, K. Cherif, S. Rebai, N.E. Kchir, Y. Nouira, N. Berrais, A. Horchani
Department of Urology & Pathology, La Rabta Hospital-University, Tunis, Tunisia
96 GLOBAL DISCREPANCIES IN PROSTATE CANCER MANAGEMENT: HOW CAN WE BRIDGE THE GAP?
J.R. Bhatt
, R.P. MacDonagh
Northampton General Hospital NHS Trust, Northampton, UK
97 INCIDENCE OF ADENOCARCINOMA OF THE PROSTATE AFTER PHOTOSELECTIVE VAPORIZATION OF THE PROSTATE FOR PROSTATE ENLARGEMENT
G. Bonkat
, M. Rieken, C.A. Rentsch, S. Wyler, T. Gasser, A. Bachmann                 
University Hospital Basel, Department of Urology, Basel, Switzerland
98 OPEN VERSUS ROBOTIC RADICAL PROSTATECTOMY IN THE PATIENTS WITH A HISTORY OF PRIOR TURP: SINGLE SURGEON’S EXPERIENCE
Y.D. Choi
, W.S. Ham, W.T. Kim, H.J. Jung, J.S. Lee                    
Department of Urology, Yonsei University, Seoul, South Korea
99 ANALYSIS OF RELATIONSHIP BETWEEN PROSTATE VOLUME AND GLEASON SCORE IN PROSTATE CANCER
Y.D. Choi
, W.S. Ham, W.T. Kim, K.H. Kim, H.J. Ju                  
Department of Urology, Yonsei University, Seoul, South Korea
100 CHEMICAL CASTRATION WITH INTRATESTICULAR INJECTION OF 20% HYPERTONIC SALINE: A MINIMALLY INVASIVE METHOD
M. Dadal
, M. Sunay, L. Emir, D. Erol                        
1st Clinic of Urology, Ministry of Health Ankara Teaching and Research Hospital, Ankara, Turkey
101 CLINICAL OUTCOME OF HIGH RISK PROSTATE ADENOCARCINOMA (T3 AND GLEASON SCORE > OR = 8)
L. Emir
, M. Sunay, M. Dadal, D. Erol                        
1st Clinic of Urology, Ministry of Health Ankara Teaching and Research Hospital, Ankara, Turkey
102 OBESITY, TESTOSTERONE AND PROSTATE CANCER
P. Eufrasio
, B. Parada, R. Patrao, F. Rolo, A. Mota                   
Department Urology Renal Transplant, Hospitals of the University of Coimbra, Coimbra, Portugal
103 IMPROVED PREDICTION OF RADICAL PROSTATECTOMY PATHOLOGICAL OUTCOMES USING A PANEL OF PROSTATE CANCER BIOMARKERS
D.M. Fanning
, Y. Fan, L. Sullivan, M. Burke, T. Lynch, H. Klocker, W. Horninger, J.M. Fitzpatrick, R.W.G. Watson
Conway Institute of Biomolecular and Biomedical Research, School of Medicine and Medical Science, University College & Department of Urology, St. James's Hospital, Dublin, Ireland
104 FUNCTIONAL GENETIC POLYMORPHISM IN THE HYPOXIA INDUCIBLE FACTOR 1 ALPHA AND PROSTATE CANCER
A. Fraga
, R. Ribeiro, F. Pina, C. Silva, F. Lobo, R. Medeiros
Urology Department, D Pedro V Military Hospital, Lisbon Medical Centre & Portuguese Institue of Oncology, Porto, Portugal
105 CIGARETTE SMOKING AND ALCOHOL INTAKE INCREASE OXIDATIVE STRESS IN PROSTATE CANCER PATIENTS
M.O. Freitas
, C. Rabaça, I. Baldeiras, T. Proença, R. Pascoal, F. Valido, A. Mota-Pinto, A. Sarmento-Ribeiro
General Pathology Institute, Faculty of Medicine, University of Coimbra, Portugal
106 CRYOSURGERY WITH SHORT TERM NEOADJUVANT ANDROGEN ABLATION AS PRIMARY TREATMENT FOR LOCALIZED PROSTATE CANCER
A. Galosi
, V. Lacetera, L. Gasparri, M. Tiroli, G. D'Anzeo, L. Franco, G. Muzzonigro
Department of Urology, Azienda Ospedali Riuniti, Ancona, Italy
107 ZD4054, A SPECIFIC ENDOTHELIN-A RECEPTOR ANTAGONIST WITH POTENTIAL FOR THE TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER
J. Growcott
, N.A. Dawson, T. Morris, D. Phung, N.D. James                    
AstraZeneca, Alderley Park, Macclesfield, UK
108 UPGRADING AND UPSTAGING OF BIOPSY GLEASON 6 PROSTATE CANCER
J.H. Hong
, C.-S. Kim, H. Ahn, M.K. Jo, H.G. Kim, S.I. Seo, K.-S. Lee              
Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
109 IMPACT OF PRETREATMENT FACTORS, BIOPSY GLEASON GRADE VOLUME INDEX AND POST TREATMENT NADIR PSA ON CAUSE-SPECIFIC AND OVERALL SURVIVAL IN PATIENTS WITH STAGE IV PROSTATE CANCER
K. Ito,
S. Miyamoto, T.Yamamoto, K. Suzuki, K. Suzuki, H. Yamanaka                  
Department of Urology, Gunma University Graduate School of Medicine, Maebashi Japan
110 PHASE III TRIAL OF DEGARELIX VS LEUPROLIDE: COMPARING SAFETY AND TOLERABILITY
P. Iversen
, J.K. Jensen, T.K. Olesen, B.-E. Persson                        
Department of Urology, University of Copenhagen, Copenhagen, Denmark
111 DEGARELIX COMPARED WITH LEUPROLIDE IN A 12-MONTH RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, PHASE III STUDY (CS21) IN PROSTATE CANCER (PCA) PATIENTS
P. Iversen
, J.K. Jensen, T.K. Olesen, B.-E. Persson                        
Ferring Pharmaceuticals & Department of Urology, University of Copenhagen, Copenhagen, Denmark
112 THE VALUE OF THE PROSTATE BIOPSY TO DIAGNOSE THE PROSTATE CANCER IN THE PATIENTS WITH HIGH PSA
Y.-S. Kim
, H.-J. Jung, J.-H. Lee, K.-K. Park                       
NHIC Ilsan Hospital, Koyang, Korea
113 A PROSPECTIVE COMPARISON STUDY OF FLUORINE 18-FLUORODEOXYGLUCOSE PET/CT AND CARBON 11-ACETATE PET/CT FOR THE LOCALIZATION OF PROSTATE CANCER:
K.H. Lee
, J.Y. Joung, K.S. Han, K.S. Cho, S.K. Kim, W.S. Park                 
Urologic Oncology Clinic, Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea
114 A PROSPECTIVE STUDY OF EGFR AS PREDICTING FACTOR ON BIOCHEMICAL RECURRENCE AFTER RRP
K.H.  Lee
, J.Y. Joung, K.S. Han, K.S. Jo, H.K. Seo, J.S. Chung, W.S. Park, J.W. Lee
National Cancer Center, Goyang, Korea
115 PREDICTION OF GLEASON SCORE UPGRADING IN LOW RISK PROSTATE CANCERS DIAGNOSED VIA MULTI (¡ 12)-CORE PROSTATE BIOPSY
S.E. Lee
, S.J. Jeong, S.-S. Byun, S.K. Hong                        
Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea
116 PREDICTION OF PATHOLOGIC TUMOR BILATERALITY IN UNILATERAL, LOW RISK PROSTATE CANCERS DIAGNOSED VIA MULTICORE PROSTATE BIOPSY
S.E. Lee
, S.J. Jeong, S.-S. Byun, S.K. Hong                        
Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea
117 THE ROLE OF FAS/FASL APOPTOTIC SYSTEM IN PROSTATE CANCER HORMONE-RESISTANCE
L. Lima
, A.M. Gomes, R. Ribeiro, A. Fraga, F. Pina, F. Lobo, F. Calais-da-Silva, R. Medeiros           
Molecular Oncology Group - IPO-Porto, Porto, Portugal
118 SALVAGE THERAPY USING HIGH INTENSITY FOCUSED ULTRASOUND FOR LOCAL RECURRENCE OF PROSTATE CANCER AFTER RADIATION THERAPY.
S. Mallick
, L. Taksin, S. Le Toquin-Bernard, O. Frachet, H. Bensadoun
CHU Urology, CHU Cote de Nacre, Caen, France
119 EFFICACY AND SAFETY OF TRANS-RECTAL HIGH INTENSITY FOCUSED ULTRASOUND IN THE TREATMENT OF LOCALIZED PROSTATE CANCER
S. Mallick
, L. Taksin, S. Le Toquin-Bernard, O. Frachet, H. Bensadoun  
CHU Urology, CHU Cote de Nacre, Caen, France
120 CORRELATION BETWEEN PROSTATE SATURATION BIOPSIES AND RADICAL PROSTATECTOMY SPECIMENS: CAN WE PREDICT THE FINAL PATHOLOGICAL OUTCOME?
S. Mallick
, F. Comoz, S. Le Toquin-Bernard, O. Frachet, C. Jeanne- Pasquier, P. Rousselot, H. Bensadoun 
CHU Urology, CHU Cote de Nacre, Caen, France
121 SERUM PSA IN COMBINATION WITH SEMINAL IL-6: PREDICTIVE VALUE FOR ASYMPTOMATIC INFLAMMATORY PROSTATITIS
R. Mandar
, P. Korrovits, K. Ausmees, M. Punab                       
Andrology Centre, Tartu University Hospital, Tartu, Estonia
122 IODINE-125 BRACHYTHERAPY (BT) WITH OR WITHOUT EXTERNAL BEAM RADIATION THERAPY (EBRT) FOR HIGH RISK PROSTATE CANCER
K. Miki
, M. Aoki, S. Egawa                           
Jikei University, Tokyo Japan
123 ONE-STOP PROSTATE CANCER ASSESSMENT CLINIC:  CLERICAL OR CLINICAL?
A. Mohammed
, I. Shergill, S. Gujral, M. Vandal
The Ayr Hospital, Ayr, UK
124 RANDOM PSA TESTING – BOON OR BANE? – A 3 YEAR UK EXPERIENCE
A. Muneer
, A. Blacklock
Department of Urology, University Hospitals of Coventry & Warwickshire (UHCW), Coventry, UK
125 CONTROVERSIES IN METASTATIC PROSTATE CANCER TREATMENT
B. Pajovic
, N. Radojevic, M. Radovic, D. Mandic                        
Forensic Medicine Department, Clinical Center of Montenegro, Podgorica, Montenegro
126 THE INCIDENCE OF ATYPICAL SMALL ACINAR PROLIFERATION (ASAP) AND ITS RISK OF PROSTATE CANCER
J.W. Park
, W. Kim, B.C. Jeong, S.I. Seo, S.S. Jeon, H.M. Lee, H.Y. Choi               
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
127 GLEASON SCORE ON BIOPSY vs RADICAL PROSTATECTOMY - RESULTS OF A CONTEMPORARY SERIES
R.F. Patrao, P.T. Nunes, P. Eufrasio, A.J. Roseiro, A.J. Mota                     
Hospitals of the University of Coimbra, Coimbra, Portugal
128 TWO YEARS BIOCHEMICAL FAILURE FREE SURVIVAL FOLLOWING HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) FOR LOCALIZED PROSTATE CANCER: PROSPECTIVE SINGLE CENTER STUDY OF 197 PATIENTS
J. Pinthus
, F. Farrokhyar, M. Hassouna, E. Woods, W. Orovan
The Department of Surgery, McMaster University, Hamilton Ontario, Canada
129 REVISITING THE RELEVANCE OF SURGICAL CASTRATION IN THE MANAGEMENT OF ADVANCED PROSTATE CANCER: WOULD SPEED AND ECONOMY SWAY THE DEBATE?
R. Rajasundaram
, N. George
Urology Department, Royal Preston Hospital, Preston, UK
130 A COMPARISON OF THE INCIDENCE AND LOCATION OF POSITIVE SURGICAL MARGINS IN LAPAROSCOPIC RADICAL PROSTATECTOMY AND RETROPUBIC RADICAL PROSTATECTOMY
E.A. Rijo Mora
, A. Francés, J. Lorente, Ó. Bielsa, L. Fumadó, J. Lloreta, O. Arango Tora
Department of Urology & Department of Pathology, Hospital del Mar, Barcelona, Spain
131 CURRENT OPINION ON CRITERIA FOR LYMPHADENECTOMY IN LOCALISED PROSTATE CANCER
W. Runneboom
, P. Braam, M. Nanlohy, W. Levens, L. Fossion
Department of Urology, Maxima Medical Center, Veldhoven, Netherlands
132 CELL ADHESION MOLECULES IN PROSTATIC CANCER: BASIS OF TUMORARCHITECTURE AND GLEASON GRADING
P.E. Stoemmer
, P. Torres-Galea                                
Forschungslabor Pathologie, Augsburg, Germany
133 ANTI-CANCER CHEMOTHERAPY GIVEN AFTER PERINEURIAL REPAIR OF INADVERTENTLY INJURED OBTURATOR NERVE HAS NO NEGATIVE EFFECT ON HEALING PROCESS OF INJURED NERVE: A CASE REPORT
M. Sunay
, A. Karabulut, L. Emir, M. Dadal‎, D. Erol                     
1st Clinic of Urology, Ministry of Health Ankara Teaching and Research Hospital, Ankara, Turkey
134 EFFECTS OF ANDROGEN AND VALPROIC ACID TREATMENT ON ANDROGEN-DEPENDENT CELL LINE (LNCAP-SF)
A. Valentini
, F. Conforti, V. Tassone, R. Miano, G. Federici, G. Vespasiani, S. Bernardini
U.O.C. Molecular Clinical Biology, Hospital University “Tor Vergata”, Rome, Italy
135 PATHOLOGICAL ASSOCIATION BETWEEN BIOPSY AND SURGICAL SPECIMENS OF PATIENTS WHO WERE DETECTED CARCINOMA IN ONLY ONE CORE BY PROSTATE NEEDLE BIOPSY
T. Yamamoto
, K. Tashiro, Y. Yamaguchi, K. Hata, H. Sasaki, J. Miki, T. Kimura, A. Furuta, K. Miki, N. Furuta, H. Takahashi, S. Egawa
Jikei University School of Medicine, Tokyo, Japan
136 PERINEURAL INVASION AND EFFECT OF RADIOTHERAPY AFTER RADICAL PROSTATECTOMY IN PT2C STAGE PROSTATE CANCER
M. Zharkovski
, M.M. Marjamigi                               
Department of Urology and Kidney Transplantation, Department of Clinical Oncology, Tartu University Hospital, Tartu, Estonia
137 THE RATE OF INCIDENTAL PROSTATE CANCER IN PATIENTS WHO UNDERWENT RADICAL CYSTOPROSTATECTOMY AND ITS CLINICAL SIGNIFICANCE
M. Sunay
, L. Emir, M. Dadal‎, D. Erol                       
1st Clinic of Urology, Ministry of Health Ankara Teaching and Research Hospital, Ankara, Turkey
                      
 Topic: TCC / Ureteroscopy
 
138
URETEROSCOPIC TREATMENT OF UPPER URINARY TCC
D. Bagley
, N. Leone, S. Hubosky
Thomas Jefferson University Hospital, Philadelphia, USA
              
 Topic: Testis Cancer
 
 139 13,17-BIS (1-CARBOXYPROPIONYL) CARBAMOYLETHYL-3,8-BIS (1-DECANYLOXYETHYL)-2,7,12,18-TETRAMETHYL -PORPHYRINATO GALLIUM (III) TO THE TESTICULAR TUMOR AND OTHER CELLS
H. Kamano
, I. Sakata                               
Kagawa University, Takamatsu, Japan
                                         
Late arrivals
 
 Topic: Prostate Cancer
 
140 BIOCHEMICAL DISEASE-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY IN INITIAL PSA> 20 NG/ML PROSTATE
CANCER PATIENTS
M. Del Canto
, J. Lorente, E.A. Rijo Mora, O. Bielsa, L. Fumadó, A. Francés, O. Arango
Department of Urology, Hospital del Mar, Barcelona Spain
141 PROGNOSTIC ROLE OF SOMATOSTATIN RECEPTOR SUBTYPES IN HUMAN PROSTATE CANCER
A. Gernone
, V. Pagliarulo, M. Battaglia
Unit of Medical Oncology, Bari, Italy
142 THE FACTOR AFFECTING RADICAL RETROPUBIC PROSTATECTOMY : BONY PELVIC SHAPE IMAGED BY MAGNETIC RESONANCE
D. Kwon
, S.B. Ryu, K. Park, S.I. Jung, S.O. Kim, K.J. Oh, C.M. Im, J.S. Joo, C.W. Yun, G.P. Kim, J.H. Noh, E.T. Kim
Chonnam National Unversity Hwasun Hospital, Gwangju, South Korea
           
143
THREE MONTHS INTERMITTENT HORMONE THERAPY +/- 5 ALPHA REDUCTASE AS AN ALTERNATE TO ACTIVE MONITORING TO SEPARATE LATENT FROM CLINICALLY SIGNIFICANT PROSTATE CANCER
T.Oliver
, B. Leibowitz, G. Shaw

Barts and London NHS Trust, London, UK

144 

COLOR DOPPLER AND MICROBUBBLE CONTRAST AGENT DO NOT IMPROVE THE CANCER DETECTION RATE IN TRANS-RECTAL PROSTATE BIOPTIC SAMPLING
G. Taverna
, M. Seveso, F. Grizzi, A. Piccinelli, G. Giusti, P. Graziotti
Department of Urology, Istituto Clinico Humanitas, Milan, Italy
145 FLUCTUATING PROSTATE-SPECIFIC ANTIGEN DO NOT DECREASE THE RISK OF PROSTATE CANCER
G. Taverna
, M. Seveso, F. Grizzi, A. Benetti, P. Graziotti   
Department of Urology, Istituto Clinico Humanitas, Milan, Italy

Home    Scientific Committee    Abstracts    Registration     Accommodation     Sponsorship & Exhibition    General Information    Contact Us   
Copyright © 2007 comtecmed.com. All rights reserved. Created by     WebStudio.co.il